News & Events

Press Releases

Show All

July 2009

July 22, 2009 Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics InternationalDownload PDF

MADISON, Wis., July 22, 2009– Cellular Dynamics International (CDI) announced today the appointment of Junying Yu, Ph.D., as senior research fellow. Her significant body of published research has shown her to be one of the leading stem cell researchers in the world. Dr. Yu’s scientific leadership will help to accelerate the company’s efforts toward harnessing the power of induced pluripotent stem (iPS) cells to reproducibly differentiate into essential cell types for drug discovery and development and eventually therapeutic use.

July 15, 2009 Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug TestingDownload PDF

MADISON, Wis., July 15, 2009– Cellular Dynamics International (CDI) today announced that it has exclusively in-licensed a US-issued patent portfolio on optimizing the stem cell differentiation selection process and on using heart cells (cardiomyocytes) in drug testing.

July 8, 2009 Cellular Dynamics International Reprograms Blood Cells into Stem CellsDownload PDF

MADISON, Wis., July 8, 2009– Researchers at Cellular Dynamics International (CDI) report the ability to generate pluripotent stem cells, which have the ability to generate all tissue types in the body, from very small volumes of ordinary human blood samples. This significant breakthrough provides a readily obtainable source of pluripotent stem cells from the millions of samples in storage at blood repositories and healthcare institutions worldwide. These findings, announced today, will be presented during a poster session beginning at 4:45 p.m. on July 10 at the ISSCR annual meeting in Barcelona, Spain.

July 1, 2009 Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening AgreementDownload PDF

MADISON, Wis., July 1, 2009– Cellular Dynamics International (CDI) and Roche announced today a significant expansion of their existing agreement to test drug development candidates for their potential to cause cardiotoxicity, or damage to heart tissue. The two-year collaboration aims to enhance drug safety testing in order to bring promising therapies to patients faster.

July 1, 2009 Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening AgreementDownload PDF

MADISON, Wis., July 1, 2009– Cellular Dynamics International (CDI) and Roche announced today a significant expansion of their existing agreement to test drug development candidates for their potential to cause cardiotoxicity, or damage to heart tissue. The two-year collaboration aims to enhance drug safety testing in order to bring promising therapies to patients faster.